Thrombotic markers as predictors for recurrent cardiovascular events after the acute coronary syndrome

Thrombotic markers as predictors for recurrent cardiovascular events after the acute coronary syndrome - TRACS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38237

Enrollment

585

Registered

2011-08-18

Start date

2012-04-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart disease myocardial ischemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Study population = Patients >18years who meet the criteria of the acute coronary syndrome: unstable angina, non ST segment elevation myocardial infarction, ST segment elevation myocardial infarction. ;Control population = Patients >18years who DON'T meet the criteria of the acute coronary syndrome, form which the ambulance personal drew blood during transport to the hospital because of high suspicion of ACS.

Exclusion criteria

Exclusion criteria: Study population = 1. Inability to attend follow-up visits at one of the participating hospitals at 1 and 6 months after inclusion. 2. Patients using anticoagulant medication (coumarines).;Control population = Patients using anticoagulant medication (coumarines)

Design outcomes

Primary

Measure	Time frame
Study parameters/endpoints: A panel of markers of coagulation will be determined (microparticles, hsCRP, interleukins, NT pro-BNP, D-dimer, flTFPI, protein S, coagulation factors) and different techniques will be used (thrombin generation and elisa based on recombinant nanobodies). The combined end points comprise cardiovascular death, recurrent myocardial infarction, a secondary coronary intervention (PCI or CABG) and ischemic stroke.	—

Measure

Time frame

Study parameters/endpoints: A panel of markers of coagulation will be determined (microparticles, hsCRP, interleukins, NT pro-BNP, D-dimer, flTFPI, protein S, coagulation factors) and different techniques will be used (thrombin generation and elisa based on recombinant nanobodies). The combined end points comprise cardiovascular death, recurrent myocardial infarction, a secondary coronary intervention (PCI or CABG) and ischemic stroke.

—

Countries

Netherlands

Outcome results